MicrosoftTeams image 47 scaled
First patient dosed for the first week in NG11-2 Phase Ib clinical trial

A Phase-1b Dose Escalation Study to Assess the Effect of NG11-2 on Radiation Induced Oral Mucositis (RIOM) in Patients with Head & Neck Cancer

26th May 2023 – VasoDynamics Ltd, the pharmaceutical company developing patient-friendly therapies for the prevention of debilitating side-effects induced by anti-cancer treatments, has obtained confirmation that the first patient has been treated with NG11-2 at the first dose level, once daily before undertaking fractional radiotherapy for 5 consecutive days in the first week of treatment. NG11-2 is well tolerated so far, and the patient is doing well. The treatment with NG11-2 is continuing alongside the radiotherapy regime. The study is investigating the safety and preliminary efficacy of NG11-2 mouthwash for reducing and preventing severe Radiation-Induced Oral Mucositis (RIOM), a well-known and debilitating side-effect of radiotherapy on patients undergoing treatment for head & neck cancer. The study consists of the dose escalation phase followed by a dose expansion phase on the recommended phase 2 dose (RP2D) that is to be chosen following the dose escalation phase.

Dr Ningfeng Fiona Li, CEO of VasoDynamics, said:

“We are delighted with the successful dosing of the first patient and that the first dose level is well tolerated so far. This represents a major milestone in the progress of our NG11-2 Phase Ib trial. We are looking forward to progressing the dose-escalation trial over the coming weeks.”

For enquiries, please contact:

Dr Ningfeng Fiona Li, CEO +44 7969132263
Gary Bower, COO +44 7960388412

Notes to Editors:

About VasoDynamics

VasoDynamics is a UK-based pharmaceutical development company focused on improving the standard of cancer care globally.  Recognising the mounting cost pressures facing healthcare payers all over the world, VasoDynamics is developing cost-effective medicines for the prevention and treatment of debilitating and often dose-limiting complications of cancer therapy, such as chemotherapy and radiotherapy-induced mucositis, dermatitis and hair-loss.  The company’s proprietary technology platform utilises the different dynamics of normal and cancerous vasculature to achieve the most effective protection of normal tissue during cancer treatment whilst enhancing anti-cancer therapy efficacy.